Q2 EPS Forecast for Corcept Therapeutics Raised by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research increased their Q2 2025 earnings estimates for Corcept Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.37 for the quarter, up from their previous estimate of $0.34. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.47 EPS, FY2025 earnings at $1.64 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.82 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $2.83 EPS and FY2027 earnings at $3.81 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. HC Wainwright reissued a “buy” rating and set a $115.00 target price on shares of Corcept Therapeutics in a research note on Thursday, February 27th. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Finally, Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.75.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $58.66 on Friday. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00. The firm has a fifty day simple moving average of $61.49 and a 200 day simple moving average of $53.81. The company has a market capitalization of $6.19 billion, a PE ratio of 46.56 and a beta of 0.61. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CORT. Norges Bank acquired a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $42,055,000. Jacobs Levy Equity Management Inc. boosted its holdings in Corcept Therapeutics by 40.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after purchasing an additional 352,947 shares during the last quarter. Braun Stacey Associates Inc. purchased a new position in Corcept Therapeutics during the fourth quarter worth about $14,935,000. FMR LLC boosted its holdings in Corcept Therapeutics by 24.6% during the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after purchasing an additional 269,074 shares during the last quarter. Finally, Synergy Asset Management LLC boosted its holdings in Corcept Therapeutics by 131.3% during the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after purchasing an additional 262,503 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the insider now directly owns 85,318 shares in the company, valued at $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of Corcept Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total transaction of $178,100.84. Following the transaction, the chief executive officer now owns 3,019,411 shares of the company’s stock, valued at $183,912,324.01. This represents a 0.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 45,627 shares of company stock valued at $2,557,674. Corporate insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.